Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793896 | 0.82 | RORC (0.56) | RORCCYP3A4CYP2C9CAPN1ALDH1A1 | |
| SCHEMBL27736730 | 0.81 | RORC (0.47) | RORCCYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL4792570 | 0.81 | RORC (0.60) | RORCCYP3A4CYP2C9CAPN1SMN1; SMN2 | |
| SCHEMBL4768479 | 0.77 | RORC (0.55) | RORCCYP3A4CYP2C9CAPN1NPC1 | |
| SCHEMBL4768485 | 0.77 | RORC (0.55) | RORCCYP3A4CYP2C9CAPN1NPC1 | |
| SCHEMBL4580698 | 0.73 | ROCK2 (0.54) | RORCHSP90AA1PARP1PARP2 | |
| SCHEMBL27715915 | 0.73 | RORC (0.46) | RORCCYP3A4CYP2C9PARP1PARP2 | |
| SCHEMBL28534560 | 0.71 | HTR7 (0.43) | RORCKCNH2HSP90AA1KDM4EALDH1A1 | |
| SCHEMBL4791898 | 0.70 | RORC (0.45) | RORCCYP3A4CYP2C9KCNH2PARP1 | |
| SCHEMBL4794096 | 0.69 | RORC (0.47) | RORCCYP3A4CYP2C9KCNH2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101268048-A | Carbazole derivatives | SERENEX INC (US) | 2008-09-17 | — | — | CN | claimed |
| EP-1924557-A2 | CARBAZOLE DERIVATIVES | Serenex, Inc. (US) | 2008-05-28 | — | — | EP | claimed |
| US-20070185184-A1 | Carbazole derivatives | SERENEX, INC. | 2007-08-09 | — | — | US | claimed |
| WO-2007035620-A2 | CARBAZOLE DERIVATIVES | SERENEX, INC. (US) | 2007-03-29 | — | — | WO | claimed |
| CN-101268048-A | Carbazole derivatives | SERENEX INC (US) | 2008-09-17 | — | — | CN | disclosed |
| EP-1924557-A2 | CARBAZOLE DERIVATIVES | Serenex, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070185184-A1 | Carbazole derivatives | SERENEX, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185184-A1 | Carbazole derivatives | SERENEX, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185184-A1 | Carbazole derivatives | SERENEX, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007035620-A2 | CARBAZOLE DERIVATIVES | SERENEX, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035620-A2 | CARBAZOLE DERIVATIVES | SERENEX, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185184-A1 | Carbazole derivatives | CCNI, MKI67, CCNB3 | RORC 224/4885CYP3A4 654/4885CYP2C9 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.